One of the proteins required for centrosome clustering is kinesin family member C1 (KIFC1/HSET), and modulation of KIFC1 stability could reduce its activity in cancer cells.

HCW Biologics Inc. has received clearance of its IND application from the FDA to initiate a first-in-human phase I trial to evaluate HCW-9302 in patients with moderate to severe alopecia areata.

KRAS G12D and G12V mutations are highly prevalent in aggressive gastrointestinal tumor types such as pancreatic cancer.

Inmed Pharmaceuticals Inc. has selected an intravitreal (IVT) formulation for INM-089 as a drug candidate to be utilized in the company’s ongoing development program targeting the treatment of dry age-related macular degeneration (AMD).

Researchers at the University of California at San Francisco have identified an RNA-binding protein that increased the translation of Myc mRNA. The authors wrote that their work, which was published online in Nature Cell Biology on Feb. 4, 2025, “transforms the understanding of the translational code in cancer and illuminates therapeutic openings to target the expression of oncogenes.” Myc is a transcription factor that regulates multiple cellular growth factors. Its overexpression is a driver event in many solid tumors, including pancreatic cancer. Drugging Myc, though, has so far proved challenging.

Lactiga Inc. has been awarded a multiyear grant by the National Institute of Allergy and Infectious Diseases (NIAID) to accelerate the advancement of the company’s lead asset, LCTG-001.